UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~February~~April 62, 2012

WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation)	333-165684 (Commission File Number)	26-2816569 (I.R.S. Employer Identification No.)
No. 365 Chengde Street, Daowai District, Harbin Heilongjiang Province, The People’s Republic of China 150020 (Address of principal executive offices) (zip code)
No. 365 Chengde Street, Daowai District, Harbin Heilongjiang Province, People’s Republic of China 150020 (Address of principal executive offices) (zip code)
	(86) 451-88355530
(Registrant’s telephone number, including area code)
	Not Applicable.
(Former name or former address, if changed since last report.)

Copies to:

Marc J. Ross, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor,

New York, NY 10006

Tel: (212) 930 9700

Fax: (212) 930 9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) £¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) £¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) £¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~February~~April 12, 2012, ~~Alpha~~Weikang ~~Capital Anstalt (“Plaintiff”)~~Bio-Technology ~~filed~~Group aCo., ~~civil~~Inc. ~~suit~~ (the ~~“Complaint”~~"Company") ~~against~~announced ~~the~~its ~~Company~~financial inresults ~~the United States District Court~~ for the ~~Central~~fiscal ~~District Court~~year ofended ~~California.~~December ~~In the Complaint~~31, Plaintiff asserts breach of contract claims against the Company based upon the Company’s purported breach of certain anti-dilution provisions of a subscription agreement (the “Subscription Agreement”)2011. In A ~~the~~copy ~~Complaint, Plaintiff seeks unspecified damages, together with injunctive relief from the Court ordering the Company to issue to it at least 100,832 shares~~ of ~~its common stock and also to reduce~~ the ~~exercise price on certain warrants owned by Plaintiff. The~~ Company’s ~~time~~press torelease ~~answer~~announcing orthese ~~otherwise~~financial ~~respond~~results tois ~~the~~attached ~~Complaint~~hereto ~~has~~as ~~not~~Exhibit ~~yet expired~~99. ~~The Company will vigorously defend the lawsuit~~1.

~~This~~In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “to be "filed”" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ~~(the “Exchange Act”)~~, or ~~incorporated~~ otherwise subject to the liabilities of that section ~~or Sections 11 and 12(a)(2) of the Securities Act of 1933~~, ~~as amended (the “Securities Act”),~~ and shall not be deemed to be incorporated by reference ininto any ~~registration~~of ~~statement~~the orCompany’s ~~other~~filings ~~document filed~~ under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, ~~regardless~~and regardless of any general incorporation language in such filings, except asto ~~shall~~the beextent expressly set forth by specific reference in such a filing.

~~SIGNATURE~~Item 9.01 Financial Statements and Exhibits.

~~Pursuant~~(d) ~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Exhibits.

Dated: February 10, 2012		WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC.
		By: /s/ Yin Wang
		Yin Wang
		Chief Executive Officer and Chairman

99.1

Press release, dated April 2, 2012, issued by Weikang Bio-Technology Group Co., Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 3, 2012		WEIKANG BIO-TECHNOLOGY GROUP COMPANY, INC.



		By: /s/ Yin Wang
		Yin Wang
		Chief Executive Officer and Chairman

Filing Compare · WEIKANG BIO-TECHNOLOGY GROUP CO., INC.